Josh Bilenker, Endpoints JPM 2020
May 4, 2021 08:22 AM EDTUpdated 10:58 AM
Startups
Bioregnum

Josh Bilenker and Jeff En­gel­man bun­dle a moth­er lode of cash for their stealthy start­up, at­tract­ing a who's who of biotech in­vestors

Josh Bilenker and Jeff En­gel­man won’t be wor­ry­ing about mon­ey for their stealthy start­up any­time soon.

Late last week the pair filed a Form D …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times